
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Red Light on the Access Autobahn
about 15 years ago
Plant Managementabout 15 years ago
The Road from No. 20about 15 years ago
Five Yearsabout 15 years ago
Spotlight on OTCsabout 15 years ago
Invarabout 15 years ago
Europe Tackles 'Advertising in Disguise' Fearsabout 15 years ago
The Drug Shortages Struggleabout 15 years ago
Euroserviceabout 15 years ago
Pharma's Visit to the Plastic Surgeonabout 15 years ago
The Pharma Revolution Recalibrated




